News

4
Jan

Genoskin CSO obtains high-profile career award

GENOSKIN CSO OBTAINS HIGH-PROFILE CAREER AWARD To start the new year in good cheer, Genoskin is proud to announce that Dr. Nicolas Gaudenzio, our Chief Scientific Officer and Principal Investigator at Infinity, has recently obtained the Arloing-Courmont-Pasteur Institute career achievement award in human biology from the Academy of Science in Lyon, France. An award to highlight innovative scientific research The
Read more
3
Jan

Better Technology for Reliable Drug Development

CREATING BETTER TECHNOLOGY FOR RELIABLE DRUG DEVELOPMENT STUDIES Changing drug development as we know it Genoskin aims to change drug development technology as we know it. We combine artificial intelligence and cutting-edge technology with live ex vivo human tissue to efficiently help pharmaceutical and biotech companies develop new drugs and vaccines in a better, faster and more cost-efficient way. And
Read more
6
Dec

Genoskin launches spatial skin biology platform MANTIS®

PRESS RELEASE - Toulouse, France & Salem, MA, USA - December 6, 2021 GENOSKIN LAUNCHES SPATIAL SKIN BIOLOGY PLATFORM MANTIS® Genoskin launches MANTIS®, a spatial biology imaging platform dedicated to skin immunology. The MANTIS® (Multiplex ANnotated Tissue Imaging System) platform was developed at Infinity (Inserm U1291, France) by a team of experts under the guidance of Dr. Nicolas Gaudenzio, who
Read more
8
Nov

Dr. Nicolas Gaudenzio is appointed Chief Scientific Officer at Genoskin

Genoskin appoints Dr Nicolas Gaudenzio as Chief Scientific Officer Today, November 8, Genoskin announces the appointment of Dr. Nicolas Gaudenzio as Chief Scientific Officer (CSO), starting in November. Dr. Gaudenzio will lead Genoskin's shift towards new activities Dr. Gaudenzio is a world-renowned researcher and expert in immunology and allergic skin inflammation. He is also principal investigator and leader of a
Read more
28
Oct

De-risking antiaging trials with ex vivo skin models

Article written by Danny Sullivan and first published in Longevity Technology on October 28th, 2021. The original article is available here. Genoskin can help de-risk antiaging trials with the only live human skin model available for subcutaneous administration testing With its proprietary ex vivo human skin technologies, French partner research organisation Genoskin says it is paving the way to “better,
Read more
6
Jul

Genoskin launches the ISR platform®

Genoskin launches the ISR platform®: the first human skin ex vivo platform to study injection site reactions (ISR) ahead of clinical trials Genoskin is evolving and aims to support the biotech and pharmaceutical industries in accelerating their drug development. Today, July 6th 2021, Genoskin announces the launch of the ISR platform®, a new pre-clinical toolbox designed to study injection site
Read more